Prometheon touts its transdermal delivery system for large molecules, prepares to launch hair growth gel

Prometheon Pharma says it has developed a breakthrough transdermal drug delivery system that can passively deliver large molecules like human growth hormone (which has a size of 2,200 daltons) across the skin. It just announced that it is preparing to launch a cosmetic hair growth gel for transdermal delivery of IGF-1 in the second half of the year. Prometheon is exploring other uses of its transdermal delivery system, especially in diabetes care. The company told FierceDrugDelivery that is actively seeking a Big Pharma partner to deploy its clinical-stage patch for transdermal delivery of insulin. Release

Suggested Articles

The new digital Abilify is a breakthrough for Proteus Digital Health and its patient-tracking products, but not so much for Abilify's maker, Otsuka.

Adamis Pharmaceuticals' EpiPen contender Symjepi, which was rejected last year before the EpiPen havoc, won approval from the FDA.

Researchers in the U.K. have developed a technique to better predict results in liver cancer when drug-laden polymer beads are used to deliver medicines.